- Home
- GDTC vs AEON Comparison
GDTC vs AEON Comparison
Compare GDTC & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDTC | AEON |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 13.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GDTC | AEON |
|---|---|---|
| Price | $0.93 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.82 |
| AVG Volume (30 Days) | 16.2K | ★ 852.5K |
| Earning Date | 04-24-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.18 |
| 52 Week High | $3.10 | $1.45 |
Technical Indicators
Market Signals| Indicator | GDTC | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 55.47 |
| Support Level | $0.73 | $0.23 |
| Resistance Level | $0.96 | $0.33 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 90.46 | 64.22 |
Price Performance
Historical ComparisonAbout GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.